Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8844573 | 0.93 | TP53 (0.59) | TRPV6TP53MDM2MEN1KMT2A | |
| SCHEMBL1002852 | 0.84 | MEN1 (0.81) | TP53MEN1KMT2ADRD2SIGMAR1 | |
| SCHEMBL17677208 | 0.83 | TRPV6 (0.50) | TRPV6TP53MDM2MEN1KMT2A | |
| SCHEMBL16272022 | 0.83 | TRPV6 (0.50) | TRPV6TP53MDM2MEN1KMT2A | |
| SCHEMBL31328408 | 0.83 | DRD4 (0.48) | TRPV6TP53MDM2MEN1KMT2A | |
| SCHEMBL13842724 | 0.80 | CYP11B2 (0.57) | DRD2CHRNB2CHRNA4CYP11B2 | |
| SCHEMBL28873570 | 0.80 | CYP11B2 (0.57) | TRPV6CCR5CHRNB2CHRNA4CYP11B2 | |
| SCHEMBL9557866 | 0.80 | CYP11B2 (0.57) | TRPV6CCR5CHRNB2CHRNA4CYP11B2 | |
| SCHEMBL6956567 | 0.80 | TP53 (0.54) | TRPV6TP53MDM2SIGMAR1CCR5 | |
| SCHEMBL15800693 | 0.79 | CHRNB2 (0.77) | TRPV6DRD2SIGMAR1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008040492-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | TRPV6 107/4885TP53 2982/4885MDM2 3910/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | TRPV6 107/4885TP53 2982/4885MDM2 3910/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | TRPV6 107/4885TP53 2982/4885MDM2 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.